补肺化瘀汤联合吉非替尼治疗EGFR突变型晚期非小细胞肺癌的临床观察

Clinical observation of Bufei Huayu decoction combined with gefitinib in the treatment of EGFR-mutant advanced non-small-cell lung cancer

目的探究补肺化瘀汤联合吉非替尼治疗EGFR突变型晚期非小细胞肺癌的临床应用价值。方法选取2017年6月至2019年6月本院收治的80例EGFR突变型晚期非小细胞肺癌患者作为研究对象,采用计算机随机分组法分为对照组与观察组,每组40例。对照组采用吉非替尼治疗,观察组在对照组基础上联合补肺化瘀汤治疗,比较两组生活质量、中医症候积分变化情况及不良事件发生率。结果治疗前,两组生活质量评分及中医症候积分比较差异无统计学意义;治疗后,两组生活生活质量评分均高于治疗前,中医症候积分均低于治疗前,且观察组生活质量评分明显高于对照组,中医症候积分明显低于对照组,差异具有统计学意义(P<0.05)。观察组不良反应发生率低于对照组,差异具有统计学意义(P<0.05)。结论对EGFR突变型晚期非小细胞肺癌患者采用补肺化瘀汤联合吉非替尼治疗,可显著改善临床症状,提升生活质量,且可减少不良反应,增强药物疗效,延缓耐药,值得临床推广应用。

Objective To explore the clinical value of Bufei Huayu decoction combined with gefitinib in the treatment of EGFR mutant advanced non-small cell lung cancer.Methods 80 patients with EGFR mutant advanced non-small cell lung cancer in our hospital from June 2017 to June 2019 were selected and they were randomly divided into control group and observation group,with 40 cases in each group.The control group was treated with gefitinib,and the observation group was treated with Bufei Huayu decoction on the basis of the control group.The quality of life,the changes in TCM syndrome scores and the incidence of adverse events were compared between the two groups.Results Before treatment,there was no significant difference in quality of life score and TCM syndrome score between the two groups;after treatment,the quality of life scores of the two groups were higher than those before treatment,and the TCM symptom scores were lower than those before treatment,and the quality of life scores of the observation group were higher than those of the control group,and the TCM symptom scores were lower than those of the control group,the difference was statistically significant(P<0.05).The incidence of adverse events in the observation group was lower than that in the control group,the difference was statistically significant(P<0.05).Conclusion Bufei Huayu decoction combined with gefitinib can significantly improve the clinical symptoms and quality of life of patients with EGFR mutant advanced non-small cell lung cancer,and can reduce adverse reactions,enhance drug efficacy and delay drug resistance,which is worthy of clinical application.